Reducing the Harm of Stress: Medications to Rescue the Prefrontal Cortex and Overcome Bad Habits

The Science of Stress: Focus on the Brain, Breaking Bad Habits, and Chronic Disease

Lu E. Jin

Department of Neurobiology, Yale School of Medicine, New Haven, Connecticut

Our brain is sensitive to stress. Both acute and chronic stress cause cognitive deficits and induce chronic disorders such as drug addiction. In a June 2011 conference at Yale entitled “The Science of Stress: Focus on the Brain, Breaking Bad Habits, and Chronic Disease,” Drs. Amy Arnsten and Sherry Mckee discussed the roles of prefrontal cortex in the treatment of stress impairments and addiction. Medications to strengthen the prefrontal function, such as prazosin and guanfacine, may reduce the harm of stress and help overcome smoking and alcohol abuse.

Stress-associated disorders are prevalent in our modern society. Many chronic diseases are induced or exaggerated by stress, such as cardiovascular disease, cancer, and depression [1]. A recent Yale Continuing Medical Education (CME†) conference in June 2011 entitled “The Science of Stress: Focus on the Brain, Breaking Bad Habits, and Chronic Disease” drew attention to new advances in neurobiological research on mechanisms underlying stress effects and proposed potential clinical treatments of stress-related chronic diseases.

To whom all correspondence should be addressed: Lu E. Jin, Department of Neurobiology, Yale School of Medicine, 200 South Frontage Road, New Haven, CT 06511; E-mail: Lu.jin@yale.edu.

†Abbreviations: CME, Continuing Medical Education; PFC, Prefrontal cortex; NE, norepinephrine; DA, dopamine; PLC, phospholipase C; IP3, inositol trisphosphate; PKC, protein kinase C; cAMP, cyclic adenosine monophosphate; PTSD, post-traumatic stress disorders; fMRI, functional magnetic resonance imaging.

Keywords: stress, smoking, prefrontal cortex, guanfacine, prazosin

Disclosure: Yale University and Arnsten receive royalties from the sale of extended release guanfacine (Intuniv), which is used for the treatment of Attention Deficit Hyperactivity Disorder in children and adolescents. Royalties are not received from the sale of the generic form of guanfacine, which is the form used in the above studies.
The talks by Dr. Amy Arnsten, Professor of Neurobiology, and Dr. Sherry McKee, Associate Professor of Psychiatry and Director of Yale Behavioral Pharmacology Laboratory, focused on the neurobiology of the prefrontal cortex (PFC) during stress. Their findings suggest that molecular modulations that strengthen PFC can rescue stress-induced cognitive deficits and thus allow subjects to overcome addictive behaviors.

Dr. Arnsten first introduced the functions of the PFC, which underlies our most advanced cognitive abilities, guiding our thoughts, actions, and emotions using working memory [2]. In alert, non-stressful conditions, the PFC exerts top-down cognitive control on other cortical regions and subcortical areas to locate attention, inhibit inappropriate actions, and regulate emotions. However, the PFC is the brain region that is most sensitive to the detrimental effects of stress exposure. During stressful conditions, the amygdala activates stress pathways in the hypothalamus and brainstem, which evoke high levels of norepinephrine (NE) and dopamine (DA) release. This impairs PFC function but strengthens amygdala function [2]. The amygdala performs a primary role in the processing and memory of emotional reactions. Thus, during stress, there is a switch from slow, thoughtful PFC regulation to the reflexive and rapid emotional responses of the amygdala and related subcortical structures.

In the past decades, the Arnsten lab aimed to identify the molecular mechanisms underlying stress-induced PFC impairment. They utilized in vivo electrophysiological recordings in monkey dorsolateral PFC when the animal was doing a working memory task (an oculomotor delayed response task, which requires the monkey to remember the location of a spatial cue and make eye movement to that location after a delay period). They could also apply drugs targeting different molecules simultaneously during recording by iontophoresis (a technique using small electric charge to deliver drugs to a restricted region) so they could test the functions of particular molecules in an active network. Two of the molecules identified that are very important for PFC function are α1-adrenergic receptors and α2A-adrenergic receptors. The α2A receptors are Gi protein-coupled receptors. When activated, they will inactivate adenyl cyclase, resulting in a reduction of intracellular cyclic adenosine monophosphate (cAMP). The α1 receptors are Gq protein-coupled receptors. Upon activation, they will activate phospholipase C (PLC), which leads to an increase in inositol trisphosphate (IP3) and calcium. This activates an enzyme called protein kinase C (PKC), which can phosphorylate many other molecules and trigger downstream effects.

They found that excessive amounts of NE during stress reduces PFC function by activating α1-adrenergic receptors. α1 agonists — phenylephrine and cirazoline — reduced PFC firing at the cellular level and impaired working memory behaviorally. To test the downstream of α1 receptor activation, they conducted co-iontophoresis of the PKC inhibitor chelerythrine and found it could reverse the phenylephrine-induced reduction in PFC neuronal firing [5]. Also, prazosin, an α1 antagonist, rescued the agonist-induced PFC loss-of-function [3,4]. Dr. Arnsten thus proposed that excessive NE release during stress would activate α1-adrenergic receptors and downstream PKC signaling, leading to weakened PFC function.

In comparison to the stressed condition, during alert, non-stressful conditions, moderate amounts of NE can activate α2A-adrenergic receptors and strengthen PFC function. α2A receptor activation reduces the level of cAMP and closes cAMP-gated hyperpolarizing ion channels on the dendritic spines, thus increasing synaptic efficacy. This leads to stronger PFC network activity [4]. They found that guanfacine, an α2A agonist, increased PFC neuronal firing and improved working memory performance. Also, guanfacine decreases impulsive responding on a delay discounting task (animals are able to inhibit an impulsive response to a small, immediate reward and wait for a larger reward) [6,7]. Thus, the activation of α2A receptors enables the animal
to make rational thoughts rather than reflexive actions. Guanfacine also can protect the animals from chronic stress. It has been shown that chronic stress harms PFC cognitive function and causes PFC grey matter loss [8]. Daily guanfacine treatment could protect prefrontal grey matter loss and cognitive performances from chronic stress in rats.

In the second part of the talk, Dr. McKee introduced the clinical applications of these molecular targets in stress-induced addictions. Stress is a primary mechanism involved in the maintenance of — and relapse to — tobacco dependence and alcohol use [9]. It has been known that stress reduces PFC grey matter and impairs the top-down rational control by PFC. Higher cumulative adverse life events is associated with lower mean grey matter volume of PFC, according to McKee. Will prazosin (α1 antagonist) or guanfacine (α2A agonist) improve stress reactivity and decrease addictive behaviors in humans by strengthening the PFC function?

Studies have shown that these two drugs do help overcome stress disorders and drug-taking habits. Prazosin reduces nightmares and clinical signs of patients with post-traumatic stress disorders (PTSD) [10]. Prazosin also decreases stress-induced alcohol craving, anxiety, and negative emotions in the laboratory [11]. Similarly, guanfacine has been shown to reduce stress reactivity, improve cognitive control, and decrease cigarette use in smokers [11]. Compared to another α2 agonist, clonidine, which is tested to reduce tobacco craving, guanfacine has a better side-effect profile, according to Dr. McKee.

Dr. McKee and colleagues conducted a study to test the drug effect on stress-induced smoking relapse by administering guanfacine or placebo daily to smokers. They found that stress reduced the ability to resist smoking in the placebo group, and this effect was attenuated by guanfacine. Stress also increased the number of cigarettes smoked in the placebo group, and the increase was attenuated by guanfacine. Guanfacine was able to reduce the stress-induced tobacco craving as well. A functional magnetic resonance imaging (fMRI) study comparing the placebo and guanfacine group showed increased activation in the anterior cingulate, ventromedial prefrontal cortex, and bilateral insula in the guanfacine group during the incongruent versus the congruent stimuli in a stroop task (e.g., an incongruent stimuli means that the word “red” printed in blue ink instead of red ink, and subjects needed to name the actual color of the word). During the 4-week treatment period, guanfacine significantly reduced cigarettes per day and improved retention, McKee said.

Thus, from basic mechanism research to clinical application, both prazosin and guanfacine demonstrate promise for the treatment of stress-induced alcohol and tobacco dependence. The medications to rescue prefrontal function thus show potential to rescue stress impairments and help overcome bad habits.

More pharmaceutical targets are expected to be identified to reduce the harm of stress and hopefully for other psychiatric disorders, such as schizophrenia and depression. However, there are still hurdles to overcome in this field. A sound understanding of the brain circuits involved in those disorders is a requirement. Knowledge of the neurochemical needs of those circuits and, if possible, the neurochemical changes in those circuits associated with the symptom is needed. However, the neurophysiological substrates of most psychiatric disorders are still poorly understood. People have known that the PFC is sensitive to stress and is impaired in many psychiatric disorders. Revealing the cellular and molecular mechanisms within the PFC is potentially helpful for developing effective drugs to treat the diseases.

There is also difficulty in the translation from basic research to human therapies. A great challenge in drug development is that the mechanisms identified in model organisms (usually mice and rats) might be different from those at work in a human being. Studies in non-human primates can be particularly advantageous in this regard. Be-
cause they are more similar to us evolutionarily, a drug that succeeds in non-human primates has a high possibility to work in humans. In fact, the exact same doses of guanfacine and prazosin that have improved cognitive functions in young monkeys are now used in humans [12].

Acknowledgments: The author would like to thank A. Arnsten, M. Wang, Y. Yang, C. Paspalas, N. Gamo for their great support and guidance in research and writing.

REFERENCES